A rare immune-related adverse event of pleural effusion after tislelizumab for non-small cell lung cancer: a case report and literature review
Meibin Wang, Xinjian Dai, Zhihui Li · 2026
Read A rare immune-related adverse event of pleural effusion after tislelizumab for non-small cell lung cancer: a case report and literature review by Meibin Wang, Xinjian Dai, Zhihui Li (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13386612.txt.
Description
Meibin Wang, Xinjian Dai, and Zhihui Li report a rare side effect of a cancer immunotherapy in this 2026 case report. A sixty year old man with squamous cell lung cancer had earlier received the checkpoint drug tislelizumab along with chemotherapy and radiation.
Six months after his last systemic treatment, fluid built up around one lung. Repeated drainage found no cancer cells in the fluid, and a scope inspection of the chest lining showed neither cancer nor radiation damage. Steroid treatment then brought the fluid under control. The authors argue the fluid was a late immune related side effect of the drug, and they urge continued watching for delayed reactions during long term immunotherapy.
Catalog record
| CREATOR | Meibin Wang, Xinjian Dai, Zhihui Li |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 15 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |